Available online 3 April 2023
Author links open overlay panel, , , , , , , , , , , , , , , , , , , Highlights•Recurrent Ig shortages require a responsible use.
•Disability and impairment scales should be used regularly to assess Ig efficacy.
•Treatment dependence should be evaluated throughout treatment.
•The minimum effective dose should be adjusted throughout the disease course.
AbstractTreatment strategies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) must be adapted on a case-to-case basis. Validated and reproducible tools for monitoring treatment response are required at diagnosis, when initiating treatment and throughout follow-up. A task force of French neurologists, experts in neuromuscular disease reference centers, was assembled to provide expert advice on the management of typical CIDP with intravenous immunoglobulins (Ig), and to harmonize treatment practices in public and private hospitals. The task force also referred to the practical experience of treating CIDP with Ig at the diagnostic, induction and follow-up stages, including the assessment and management of Ig dependence, and following the recommendations of the French health agency.
KeywordsCIDP
IVIg
Treatment
Maintenance
Efficacy criteria
MCIDs
AbbreviationsCIDPchronic inflammatory demyelinating polyradiculoneuropathy
EANEuropean Academy of Neurology
IVIgintravenous immunoglobulin
INCATInflammatory Neuropathy Cause and Treatment
MCIDminimum clinically important difference
MRCMedical Research Council
PNDSProtocole National de Diagnostic et de Soins (French national diagnosis and care protocol)
PNSPeripheral Nerve Society
MCMMultidisciplinary Consultation Meetings
R-ODSRasch-built Overall Disability Score
© 2023 The Authors. Published by Elsevier Masson SAS.
留言 (0)